Optimizing TNFα antagonist therapy in patients with spondyloarthritis: Why and how?

Joint Bone Spine

Volumn 78, Issue 3, 2011, Pages 225-227

  Wendling, Daniel ^a   Prati, Clément ^a   Goupille, Philippe ^b   Mulleman, Denis ^b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Spondyloarthritis; TNF antagonists; Treatment

Indexed keywords

C REACTIVE PROTEIN; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; EDITORIAL; HUMAN; LONGITUDINAL STUDY; NITROGEN NUCLEAR MAGNETIC RESONANCE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SACROILIITIS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SPONDYLITIS, ANKYLOSING; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955525830     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.02.013     Document Type: Editorial

References (31)

1. McLeod C., Bagust A., Boland A., et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007, 11:1-158.
2. Gérard S., le Goff B., Maugars Y., et al. Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A " real life" retrospective study on 175 patients. Joint Bone Spine 2008, 75:680-687.
3. Griffoul I., Giraudeau B., Mulleman D., et al. Infliximab for treating axial spondylarthropathy in everyday practice. Joint Bone Spine 2009, 76:39-43.
4. Wendling D. Interleukin-1: a new therapeutic target for ankylosing spondylitis?. Joint Bone Spine 2005, 72:357-358.
5. Song I.H., Heldmann F., Rudwaleit M., et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010, 62:1290-1297.
6. Song I.H., Heldmann F., Rudwaleit M., et al. Treatment of active ankylosing spondylitis with abatacept. An open label 24-week study. Ann Rheum Dis 2010, 69(Suppl 3):60.
7. Haibel H., Sieper J. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?. Curr Opin Rheumatol 2010, 22:388-392.
8. Goupille P., Pham T., Claudepierre P., et al. A plea for reason in using magnetic resonance imaging for the diagnostic and therapeutic management of spondyloarthropathies. Joint Bone Spine 2009, 76:123-125.
9. Claudepierre P., Wendling D. Are inflammation and ossification on separate tracks in ankylosing spondylitis?. Joint Bone Spine 2008, 75:520-522.
10. Keeling S., Oswald A., Russell A.S., et al. Prospective observational analysis of the efficacy and safety of low-dose (3mg/kg) infliximab in ankylosing spondylitis: 4-year follow-up. J Rheumatol 2006, 33:558-561.
11. Jois R.N., Leeder J., Gibb A., et al. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective. Rheumatology (Oxford) 2006, 45:1566-1569.
12. Inman R.D., Maksymowych W.P. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 2010, 37:1203-1210. CANDLE Study Group.
13. Tenga G, Goëb V, Lequerré T.et al. A 3 mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs. Joint Bone Spine. 2010;78:50-5.
14. Lee J., Noh J.W., Hwang J.W., et al. Extended dosing of etanercept 25mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol 2010, 29:1149-1154.
15. Spadaro A, Punzi L, Marchesoni A., et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford) 2010, 49:1107-1111.
16. Rudwaleit M., Van den Bosch F., Kron M., et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010, 12:R117.
17. Breban M., Ravaud P., Claudepierre P., et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008, 58:88-97.
18. Lauféron F., Ternant D., Wendling D., et al. Methotrexate does not improve the pharmacokinetics of infliximab in ankylosing spondylitis. Ann Rheum Dis 2010, 69(Suppl 3):60.
19. Van der Heijde D., Schiff M.H., Sieper J., et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to two years: long-term results from the ATLAS trial. Ann Rheum Dis 2009, 68:922-929.
20. Collantes-Estevez E., Muñoz-Villanueva M.C., Zarco P., et al. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. Rheumatology (Oxford) 2005, 44:1555-1558.
21. Navarro F., Torre Alonso J., Fdez Sueiro L., et al. A 12-week randomized, double-blind, multicenter study to evaluate the early effect of etanercept 100mg vs 50mg weekly in subjects with ankylosing spondylitis. Ann Rheum Dis 2010, 69(Suppl 3):58.
22. Davis J.C., Van der Heijde D.M., Dougados M., et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005, 32:1751-1754.
23. Rudwaleit M., Schwarzlose S., Hilgert E.S., et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008, 67:1276-1281.
24. Kristensen L., Karlsson J.A., Englund M., et al. Presence of peripheral arthritis and male sex predict continuation of anti-TNF therapy in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2010, 62:1362-1369.
25. Lord P.A., Farragher T.M., Lunt M., et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010, 49:563-570.
26. Vastesaeger N., van der Heijde D., Inman R., et al. Identification of anti-TNF candidates based on predicted response and remission in ankylosing spondylitis. Ann Rheum Dis 2010, 69(Suppl 3):58.
27. Chu Miow Lin D., Mulleman D., Azzopardi N., et al. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Scand J Rheumatol 2010, 39:97-98.
28. Seitz M., Wirthmüller U., Möller B., et al. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007, 46:93-96.
29. De Vries M.K., Van Eijk I.C., Van der Horst-Bruinsma I.E., et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009, 61:1484-1490.
30. De Vries M.K., Brouwer E., Van der Horst-Bruinsma I.E., et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009, 68:1787-1788.
31. De Vries M.K., Wolbink G.J., Stapel S.O., et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007, 66:1252-1254.